Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval

Anabel Cortes-Blanco; Concha Prieto-Yerro; Raul Martinez-Lazaro; Javier Zamora; Adolfo Jiménez-Huete; Marion Haberkamp; Johannes Pohly; Harald Enzmann; Jörg Zinserling; Valerie Strassmann; Karl Broich

doi:10.1016/j.jalz.2013.09.007

Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval

Anabel Cortes-Blanco, Concha Prieto-Yerro, Raul Martinez-Lazaro, Javier Zamora, Adolfo Jiménez-Huete, Marion Haberkamp, Johannes Pohly, Harald Enzmann, Jörg Zinserling, Valerie Strassmann, Karl Broich

Metabolism and Systems Research

Research output: Contribution to journal › Article › peer-review

Abstract

Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).

Original language	English
Pages (from-to)	s395-s399
Journal	Alzheimer's & Dementia
Volume	10
Issue number	5s
DOIs	https://doi.org/10.1016/j.jalz.2013.09.007
Publication status	Published - Oct 2014

Access to Document

10.1016/j.jalz.2013.09.007

Cite this

Cortes-Blanco, A., Prieto-Yerro, C., Martinez-Lazaro, R., Zamora, J., Jiménez-Huete, A., Haberkamp, M., Pohly, J., Enzmann, H., Zinserling, J., Strassmann, V., & Broich, K. (2014). Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval. Alzheimer's & Dementia, 10(5s), s395-s399. https://doi.org/10.1016/j.jalz.2013.09.007

@article{e8497e68f0904f84abbc395b442b4e26,

title = "Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval",

abstract = "Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).",

author = "Anabel Cortes-Blanco and Concha Prieto-Yerro and Raul Martinez-Lazaro and Javier Zamora and Adolfo Jim{\'e}nez-Huete and Marion Haberkamp and Johannes Pohly and Harald Enzmann and J{\"o}rg Zinserling and Valerie Strassmann and Karl Broich",

year = "2014",

month = oct,

doi = "10.1016/j.jalz.2013.09.007",

language = "English",

volume = "10",

pages = "s395--s399",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "5s",

}

Cortes-Blanco, A, Prieto-Yerro, C, Martinez-Lazaro, R, Zamora, J, Jiménez-Huete, A, Haberkamp, M, Pohly, J, Enzmann, H, Zinserling, J, Strassmann, V & Broich, K 2014, 'Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval', Alzheimer's & Dementia, vol. 10, no. 5s, pp. s395-s399. https://doi.org/10.1016/j.jalz.2013.09.007

TY - JOUR

T1 - Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval

AU - Cortes-Blanco, Anabel

AU - Prieto-Yerro, Concha

AU - Martinez-Lazaro, Raul

AU - Zamora, Javier

AU - Jiménez-Huete, Adolfo

AU - Haberkamp, Marion

AU - Pohly, Johannes

AU - Enzmann, Harald

AU - Zinserling, Jörg

AU - Strassmann, Valerie

AU - Broich, Karl

PY - 2014/10

Y1 - 2014/10

N2 - Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).

AB - Florbetapir (18F) for brain amyloid positron emission tomography (PET) imaging has been recently approved in Europe to estimate β-amyloid neuritic plaque density in the brain when the subject is still alive. Such density is one of the key issues for the definitive diagnosis of Alzheimer's disease (AD) at autopsy. This capability of florbetapir (18F) is regarded as a significant improvement in the diagnostic procedures for adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive impairment. The current paper highlights the specific characteristics of the European marketing authorization of florbetapir (18F).

U2 - 10.1016/j.jalz.2013.09.007

DO - 10.1016/j.jalz.2013.09.007

M3 - Article

SN - 1552-5260

VL - 10

SP - s395-s399

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 5s

ER -

Florbetapir (18F) for brain amyloid positron emission tomography: Highlights on the European marketing approval

Abstract

Access to Document

Fingerprint

Cite this